Get the Stockscreener App
26.34
0.25%
+0.24
After Hours:
26.25
-0.09
-0.34%
Pacira BioSciences Inc stock is currently priced at $26.34, with a 24-hour trading volume of 354.55K.
It has seen a +0.25% increased in the last 24 hours and a -11.22% declined in the past month.
The chart indicates a potential bullish trend, as the stock is below the $26.34 pivot point. If it approaches the $25.84 support level, significant changes may occur.
Pacira BioSciences Inc Stock (PCRX) Financials Data
Pacira BioSciences Inc (PCRX) Revenue 2024
PCRX reported a revenue (TTM) of $674.98 million for the quarter ending December 31, 2023, a +1.22% rise year-over-year.
Pacira BioSciences Inc (PCRX) Net Income 2024
PCRX net income (TTM) was $41.95 million for the quarter ending December 31, 2023, a +163.72% increase year-over-year.
Pacira BioSciences Inc (PCRX) Cash Flow 2024
PCRX recorded a free cash flow (TTM) of $139.49 million for the quarter ending December 31, 2023, a +21.09% increase year-over-year.
Pacira BioSciences Inc (PCRX) Earnings per Share 2024
PCRX earnings per share (TTM) was $0.83 for the quarter ending December 31, 2023, a +167.74% growth year-over-year.
Pacira BioSciences Inc Stock (PCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Mar 07 '24 |
Sale |
30.81 |
28,257 |
870,598 |
112,127 |
| PACE GARY W | Director |
Mar 06 '24 |
Sale |
29.67 |
1,066 |
31,628 |
140,384 |
| WINSTON ROY | Chief Medical Officer |
Aug 02 '23 |
Sale |
34.88 |
509 |
17,751 |
52,440 |
| Riker Lauren Bullaro | Senior Vice President, Finance |
Jul 05 '23 |
Sale |
38.91 |
643 |
25,019 |
22,687 |
| Riker Lauren Bullaro | Senior Vice President, Finance |
Jun 14 '23 |
Sale |
38.42 |
6,366 |
244,606 |
22,687 |
| Williams Kristen Marie | Chief Administrative Officer |
Jun 14 '23 |
Sale |
37.03 |
6,467 |
239,473 |
25,375 |
| Kronenfeld Mark A. | Director |
Jun 08 '23 |
Option Exercise |
29.90 |
15,000 |
448,500 |
32,897 |
| Kronenfeld Mark A. | Director |
Jun 08 '23 |
Sale |
37.04 |
15,000 |
555,600 |
17,897 |
| STACK DAVID M | CEO and Chairman |
Jun 07 '23 |
Sale |
37.87 |
5,326 |
201,669 |
153,781 |
| WINSTON ROY | Chief Medical Officer |
Jun 07 '23 |
Sale |
37.87 |
1,857 |
70,315 |
41,356 |
Pacira BioSciences Inc Stock (PCRX) Latest News
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Benzinga
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Zacks Investment Research
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
GlobeNewswire Inc.
Navigating 4 Analyst Ratings For Pacira BioSciences
Benzinga
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Zacks Investment Research
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
Zacks Investment Research
About Pacira BioSciences Inc
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
COMPANY PROFILE
NamePacira BioSciences Inc
SectorHealthcare (1205)
Industry
Webpacira.com
Phone973-254-3560
Employee489
SEC filings
Latest SEC Filings
Next earning date2024-05-01
Address5 Sylvan Way, Suite 300, Parsippany, NJ, United States (7054)
4.57%
1.09%
Cap:
|
Volume (24h):